RT Journal Article SR Electronic T1 Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive Summary JF The Journal of Rheumatology JO J Rheumatol FD The Journal of Rheumatology SP 751 OP 754 DO 10.3899/jrheum.180784 VO 46 IS 7 A1 Kim A. Papp A1 Boulos Haraoui A1 Deepali Kumar A1 John K. Marshall A1 Robert Bissonnette A1 Alain Bitton A1 Brian Bressler A1 Melinda Gooderham A1 Vincent Ho A1 Shahin Jamal A1 Janet E. Pope A1 A. Hillary Steinhart A1 Donald C. Vinh A1 John Wade YR 2019 UL http://www.jrheum.org/content/46/7/751.abstract AB The use of immunosuppressive therapies for immune-mediated disease is associated with an elevated risk of infections and related comorbidities. While many infectious diseases can generally be prevented by vaccines, immunization rates in this specific patient population remain suboptimal, due in part to uncertainty about their efficacy or safety under these clinical situations. To address this concern, a multidisciplinary group of Canadian physicians with expertise in dermatology, gastroenterology, infectious diseases, and rheumatology developed evidence-based clinical guidelines on vaccinations featuring 13 statements that are aimed at reducing the risk of preventable infections in individuals exposed to immunosuppressive and immunomodulatory agents.